Osiris Receives FDA Clearance To Broaden Prochymal Expanded Access Program
Jan 19th, 2009 | By buddy1 | Category: Children's Health, Health & Wellness NewsOsiris Therapeutics, Inc. (NASDAQ: OSIR) announced U.S. Food and Drug Administration (FDA) clearance to broaden its expanded access program (EAP) for Prochymal, now making the investigational stem cell product available to adults with life-threatening Graft vs. Host Disease (GvHD). In May of 2008, FDA approved the first Prochymal EAP for the treatment of pediatric GvHD [...] Read more »



